SynAct Receives Notice Of Allowance For Grant Of U.S. Patent
View all comments(0)
April 23 (Reuters) - SynAct Pharma AB SYNACT.ST:
SYNACT RECEIVES NOTICE OF ALLOWANCE FOR GRANT OF US PATENT COVERING RESOMELAGON (AP1189) COMBINATION THERAPY
US PATENT, WHEN ISSUED, CAN BE ENFORCED AT LEAST UNTIL 2040
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

U.S. April CPI Preview: Fed May Abandon Rate Cuts Until 2026?

Copper Prices Near All-Time Highs. Citi: If Strait of Hormuz Is Unblocked, Price Will Rise to $15,000 by Year-End

Tradingkey






Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.